SCHEMBL3269094

SCHEMBL3269094

NC(=O)COC(=O)NCC1CCN(c2ccc(-c3ccc(F)cc3)cn2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CKS1B P61024 7/20 0.47
▸ SKP1 P63208 7/20 0.47
▸ SKP2 Q13309 7/20 0.47
▸ TDP1 Q9NUW8 2/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ GRIN2B Q13224 1/20 0.41
▸ TDO2 P48775 1/20 0.41
▸ FGFR3 P22607 1/20 0.41
▸ KDR P35968 1/20 0.41
▸ HDAC6 Q9UBN7 2/20 0.40
▸ SCD O00767 1/20 0.40
▸ CHRM4 P08173 1/20 0.40
▸ KDM1A O60341 1/20 0.40
▸ HDAC10 Q969S8 1/20 0.40
▸ HDAC3 O15379 1/20 0.40
▸ HDAC2 Q92769 1/20 0.40
▸ KCNH2 Q12809 2/20 0.40
▸ DGAT1 O75907 1/20 0.40
▸ ADORA2A P29274 1/20 0.40
▸ CETP P11597 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3265642 0.91 CKS1B (0.51) CKS1BSKP1SKP2KDM1ACETP
SCHEMBL3266252 0.90 CHRM4 (0.49) CKS1BSKP1SKP2TDP1L3MBTL1
SCHEMBL3265677 0.86 TDO2 (0.51) CKS1BSKP1SKP2TDP1L3MBTL1
SCHEMBL3269155 0.84 CHIT1 (0.42) CKS1BSKP1SKP2L3MBTL1CHRM4
SCHEMBL3265671 0.84 DEGS1 (0.49) CKS1BSKP1SKP2L3MBTL1
SCHEMBL3266209 0.84 CKS1B (0.44) CKS1BSKP1SKP2KDM1ACETP
SCHEMBL1729030 0.83 CKS1B (0.55) CKS1BSKP1SKP2GRIN2BTDO2
SCHEMBL3265636 0.83 KDM4E (0.58) TDP1L3MBTL1CHRM4CETP
SCHEMBL3266878 0.83 CKS1B (0.45) CKS1BSKP1SKP2L3MBTL1HDAC6
SCHEMBL3266247 0.82 HRH3 (0.46) CKS1BSKP1SKP2KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120004207-A1 THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES SANOFI-AVENTIS (FR) 2012-01-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004207-A1 THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES CLCN2, CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 CKS1B 1534/4885SKP1 4286/4885SKP2 2651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback